scholarly journals Could recurrent aphthous stomatitis be linked to cancer development?

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Emily Norton
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Aphthous Stomatitis ◽  
Aphthous Stomatitis ◽  
Cancer Case ◽  
Brca Mutations ◽  
Ovarian Cancer Case ◽  
The Family ◽  
History Of ◽  
Oral Cancer Screening ◽  
Practical Implications

Background: Recurrent aphthous stomatitis is a common multifactorial oral mucosal disorder. Genetic and local factors causing RAS may contribute to the development of cancer. This study aims to explore this connection by examining a family with a history of RAS and ovarian cancer.  Case Description: The family described in the case exhibits a history of minor recurrent aphthous stomatitis. The severity of this condition increases with each generation. One member of the family has no history of RAS but was diagnosed with ovarian cancer. Genetic testing for BRCA mutations was negative indicating a different genetic cause of the cancer. All affected members of the family indicate high levels of stress or difficulty responding to stressful situations. No treatment for RAS was performed due to its self-limiting nature.  Practical Implications: Further research is needed before dentists begin to tell their patients with RAS they may be at higher risk of developing cancer. Diligent oral cancer screening and stress management counseling can decrease the risk to the patient.

scholarly journals Novel and Recurrent BRCA1/BRCA2 Germline Mutations in Patients with Breast /Ovarian Cancer: A Series from the South of Tunisia

2020 ◽  
Author(s):  
Dorra Ben Ayed-Guerfali ◽  
Wala Ben Kridis-Rejab ◽  
Nihel Ammous-Boukhris ◽  
Wajdi Ayadi ◽  
Slim Charfi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Germline Mutations ◽  
Brca Mutations ◽  
Mutation Carriers ◽  
Counseling And Testing ◽  
Recurrent Mutations ◽  
Tunisian Patients ◽  
History Of ◽  
Brca1 Brca2

Abstract Background: The incidence of breast/ovarian cancer is increasing in Tunisia especially in young women and mostly those with family history. However, the spectrum of BRCA mutations remains little explored in Tunisian patients in particular in the southern region. Methods: We sequenced the entire coding regions of BRCA1and BRCA2 genes using Next Generation Sequencing (NGS) in 134 selected patients with breast/ovarian cancer. Results: Among the 134 patients, 19 (14.17%) carried pathogenic mutations (10 are BRCA1 mutation carriers and 9 are BRCA2 mutation carriers) that are mainly frameshisft indel (76.9%). Interestingly, 5 out of the 13 variants (38.46%) were found at least twice in unrelated patients, as the c.1310-1313 delAAGA in BRCA2 and the c.5030_5033 delCTAA that has been identified in 4/98 BC patients and in 3/15 OC patients from unrelated families with strong history of cancer. Besides recurrent mutations, 6 variant (4 in BRCA1 and 2 in BRCA2) were not reported previously. Furthermore, 3 unrelated patients carried the VUS c.9976A>T, (K3326*) in BRCA2 exon 27. BRCA carriers correlated significantly with tumor site (p=0.029) and TNBC cases (p=0.008). In the groups of patients (31-40 y and 41-50 y), BRCA1 mutations occurred more frequently in patients with OC than those with BC, and conversely BRCA2 carriers are mostly affected with BC (p=0.001 and p=0.044 respectively).Conclusions: The overall frequency of the BRCA germline mutations was 14.17% in patients with high risk of breast /ovarian cancer. We identified recurrent mutations as the c.1310_1313 delAAGA in BRCA2 gene and the c.5030_5033 delCTAA in BRCA1 gene that were found in 4% and 20% of familial BC and OC respectively. Our data will contribute in the implementation of genetic counseling and testing for families with high-risk of breast/ovarian cancer.

scholarly journals RECURRENT APHTHOUS STOMATITIS RELATED TO PSYCHOLOGICAL STRESS, FOOD ALLERGY AND GERD

2019 ◽  
Vol 6 ◽  
pp. 45
Author(s):  
Rina Kartika Sari ◽  
Diah Savitri Ernawati ◽  
Bagus Soebadi
Keyword(s):  
Food Allergy ◽  
Psychological Stress ◽  
Oral Mucosa ◽  
Recurrent Aphthous Stomatitis ◽  
Predisposing Factors ◽  
Aphthous Stomatitis ◽  
Cow Milk ◽  
Esophageal Mucosa ◽  
History Of ◽  
Multiple Ulcers

Background: Recurrent Aphthous Stomatitis (RAS) is inflammation in oral mucosa characterized by recurrent single or multiple ulcers that usually affected in non keratinized mucosa. Etiology RAS is unknown but psychological stress, allergy, and gastrointestinal disease can be predisposing factors Case Management: A 23rd years old complained recurrent oral ulcer with free ulcer period for 3-5 days. The patient had a history of food allergy, GERD and psychological stress. Intraoral examination showed recurrent multiple ulcers in variation site of the mouth. DASS 42 screening showed high stress and high anxiety. Skin Prick Test showed positive allergy to kapok, beef, chicken, cow milk, white egg, duck egg, shrimp, cob fish, milkfish, chocolate, and peanut. Ulcers treated with nonsteroid antiinflammation Aloe Vera gel and stress management by reading assignment method.Discussion: Psychological stress altered the immune system so oral mucosa prone to inflammation, and make the history of GERD getting worse. Stress causes cortisol secretion that changes the imbalance of proinflammatory and antiinflammatory cytokines. Oral mucosa becomes more susceptible to hypersensitivity. In addition, stress decreased oral and esophageal mucosa resistance to GERDConclusion: RAS triggered by psychological stress, allergy, and GERD. Treatment of RAS is by elimination predisposing factors to prevent recurrence.

scholarly journals A Robust and Versatile Automated Glycoanalytical Technology for Serum Antibodies and Acute Phase Proteins: Ovarian Cancer Case Study

2019 ◽  
Vol 18 (11) ◽  
pp. 2191-2206 ◽  
Author(s):  
Róisín O'Flaherty ◽  
Mohankumar Muniyappa ◽  
Ian Walsh ◽  
Henning Stöckmann ◽  
Mark Hilliard ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Acute Phase ◽  
Acute Phase Proteins ◽  
Cancer Case ◽  
Serum Antibodies ◽  
Ovarian Cancer Case

scholarly journals Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
K. N Srinivasan ◽  
Amit Rauthan ◽  
R. Gopal
Keyword(s):  
Ovarian Cancer ◽  
Cancer Case ◽  
First Line Therapy ◽  
Ovarian Cancer Case ◽  
First Case ◽  
Long Term Follow Up ◽  
Third Line ◽  
Line Chemotherapy

Background. Ovarian cancer is the ninth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Albumin-bound paclitaxel is known to increase intratumoral concentration of the paclitaxel by a receptor-mediated transport process across the endothelial cell wall, thereby breaching the blood/tumor interface. We present below three cases in which nab-paclitaxel based chemotherapy has been used in different settings for patients with ovarian cancer.Case Presentation. In the first case nab-paclitaxel was used along with carboplatin in adjuvant setting, in the second case, nab-paclitaxel was used along with carboplatin and bevacizumab as second line chemotherapy in a relapsed ovarian cancer case, and the third case delineates the use of nab-paclitaxel along with cisplatin as third line chemotherapy.Conclusion. In all the three scenarios, patients tolerated the chemotherapy well, as well as responding well to nab-paclitaxel based chemotherapy. The patients are currently on long-term follow-up and have been having an uneventful postchemotherapy.

scholarly journals Intestinal lymphangitis carcinomatosa related to ovarian cancer: Case report and review of the literature

2020 ◽  
Vol 33 ◽  
pp. 100606
Author(s):  
Ricardo Pedrini Cruz ◽  
Gustavo Peretti Rodini ◽  
Margarete Duarte da Rosa ◽  
Vinicius Duarte Cabral ◽  
Eduardo Cambruzzi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Cancer Case ◽  
Review Of The Literature ◽  
Ovarian Cancer Case ◽  
Lymphangitis Carcinomatosa

scholarly journals European American Stratification in Ovarian Cancer Case Control Data: The Utility of Genome-Wide Data for Inferring Ancestry

PLoS ONE ◽  
2012 ◽  
Vol 7 (5) ◽  
pp. e35235 ◽  
Author(s):  
Paola Raska ◽  
Edwin Iversen ◽  
Ann Chen ◽  
Zhihua Chen ◽  
Brooke L. Fridley ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Control ◽  
Cancer Case ◽  
European American ◽  
Control Data ◽  
Ovarian Cancer Case ◽  
Genome Wide ◽  
Genome Wide Data

Second primary malignant neoplasm in patient with ovarian cancer – case report

2017 ◽  
Vol 6 (1) ◽  
pp. 43-47
Author(s):  
Przemysław Hubert Krawczyk ◽  
Marcin Braun ◽  
Dariusz Kaczmarczyk
Keyword(s):  
Ovarian Cancer ◽  
Malignant Neoplasm ◽  
Cancer Case ◽  
Laboratory Diagnostics ◽  
Second Primary ◽  
Histopathological Diagnosis ◽  
Malignant Tumours ◽  
Ovarian Cancer Case ◽  
Multiple Primary ◽  
Second Tumor

Increase in the occurrence of multiple primary malignant tumours is associated with significant extention of survival rate among patients treated for malignant neoplasm. Treatment of multiple primary malignant tumours demands precise clinical evaluation, imaging, laboratory diagnostics and histopathological evaluation of the lesion. In the presented case immunohistochemical staining of lymphatic metastasis from nasopharyngeal carcinoma was mimicking distant metastasis from poorly differentiated ovarian cancer. It impeded histopathological diagnosis and required additional imaging enriched by PET-CT, which allowed the visualization of the second tumor.

Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1547-1547
Author(s):  
Zachary Phillip Schwartz ◽  
Mae Zakhour ◽  
Andrew John Li ◽  
Christine S. Walsh ◽  
Bj Rimel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Susceptibility ◽  
Brca Mutation ◽  
Susceptibility Genes ◽  
Brca Mutations ◽  
Cancer Susceptibility Genes ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
History Of ◽  
Risk Reducing

1547 Background: Risk reducing gynecologic surgery (RRSO) is standard of care for women with BRCA mutations. The optimal management for women with non-BRCA ovarian cancer susceptibility mutations remains unclear. We sought to characterize the practice patterns for these women at our two institutions. Methods: Women with germline ovarian cancer susceptibility genes who had a RRSO were identified from 1/2000-1/2019 in an IRB approved study. All patients were asymptomatic with no suspicion for malignancy at time of RRSO. Clinico-pathologic characteristics were extracted from the medical records. Continuous variables were analyzed with Kruskal-Wallis and categorical variables analyzed with chi square and t-tests. Results: 152 BRCA1, 95 BRCA2, and 63 Non-BRCA mutation carriers were identified—50 Lynch (22 MLH1, 13 MSH2, 13 MSH6, 2 PMS2) and 13 Other (6 BRIP1, 2 RAD51C, 5 RAD51D). There was no difference between age at testing, age at RRSO, and interval between testing and RRSO between groups. Genetic counseling was higher in Non-BRCA patients. Family history of ovarian cancer was more common in women with BRCA1 and Other germline mutations compared to BRCA2 and Lynch. Family and personal history of breast cancer was high in all groups except Lynch carriers. Prophylactic mastectomy was seen mostly in BRCA mutation carriers. Concomitant hysterectomy was performed in the majority of women (BRCA1 59%, BRCA2 57%, and Other 62%), with the highest frequency in Lynch carriers (86%, p<.01). Occult cancer was only seen in BRCA mutation carriers: BRCA1 (7%), BRCA2 (2%), Lynch (0%), Other (0%). Conclusions: In this cohort, women with Non-BRCA mutations are managed similarly to women with BRCA mutations. We observed no occult cancers in Non-BRCA patients. The optimal role of surgery as a risk reducing strategy in this group requires further study. [Table: see text]

scholarly journals A successful ovarian cancer case

2021 ◽  
Vol 6 (2) ◽  
Keyword(s):  
Ovarian Cancer ◽  
Electrical Properties ◽  
Cancer Diagnostics ◽  
Cancer Case ◽  
Ovarian Cancer Case

A lady discovered she had ovarian cancer in 2016 and was treated by CellSonic. The tumour remained big and had to be surgically removed after the cancer was stopped. Since then, cancer diagnostics have progressed and the electrical properties can now be easily detected allowing CellSonic to advance from stopping cancer in a patient to stopping cancer in a population. The patient is well and has approved this article.

Sign in / Sign up

Export Citation Format

Share Document